Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure - PubMed (original) (raw)
Clinical Trial
doi: 10.1210/jcem.83.2.4539.
L Lönn, J O Jansson, G Murphy, D Wyss, D Krupa, K Cerchio, W Polvino, B Gertz, I Boseaus, L Sjöström, B A Bengtsson
Affiliations
- PMID: 9467542
- DOI: 10.1210/jcem.83.2.4539
Clinical Trial
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
J Svensson et al. J Clin Endocrinol Metab. 1998 Feb.
Abstract
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3. The effects on cortisol secretion were transient. Changes in body composition and energy expenditure were of an anabolic nature, with a sustained increase in fat-free mass and a transient increase in basal metabolic rate. Further studies are needed to evaluate whether a higher dose of MK-677 or a more prolonged treatment period can promote a reduction in body fat.
Similar articles
- Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
Svensson J, Jansson JO, Ottosson M, Johannsson G, Taskinen MR, Wiklund O, Bengtsson BA. Svensson J, et al. J Clin Endocrinol Metab. 1999 Jun;84(6):2028-33. doi: 10.1210/jcem.84.6.5799. J Clin Endocrinol Metab. 1999. PMID: 10372705 Clinical Trial. - Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA. Svensson J, et al. J Bone Miner Res. 1998 Jul;13(7):1158-66. doi: 10.1359/jbmr.1998.13.7.1158. J Bone Miner Res. 1998. PMID: 9661080 Clinical Trial. - MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. Murphy MG, et al. J Clin Endocrinol Metab. 1998 Feb;83(2):320-5. doi: 10.1210/jcem.83.2.4551. J Clin Endocrinol Metab. 1998. PMID: 9467534 Clinical Trial. - Metabolic effects of oestrogens: impact of the route of administration.
Ho KK, O'Sullivan AJ, Wolthers T, Leung KC. Ho KK, et al. Ann Endocrinol (Paris). 2003 Apr;64(2):170-7. Ann Endocrinol (Paris). 2003. PMID: 12773957 Review. - Metabolic actions of growth hormone: direct and indirect.
Berneis K, Keller U. Berneis K, et al. Baillieres Clin Endocrinol Metab. 1996 Jul;10(3):337-52. doi: 10.1016/s0950-351x(96)80470-8. Baillieres Clin Endocrinol Metab. 1996. PMID: 8853443 Review.
Cited by
- Medium-chain triglycerides (8:0 and 10:0) increase muscle mass and function in frail older adults: a combined data analysis of clinical trials.
Ezaki O, Abe S. Ezaki O, et al. Front Nutr. 2023 Dec 4;10:1284497. doi: 10.3389/fnut.2023.1284497. eCollection 2023. Front Nutr. 2023. PMID: 38111605 Free PMC article. - Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature.
Sotorník R, Suissa R, Ardilouze JL. Sotorník R, et al. Clin Diabetes. 2022 Summer;40(3):373-379. doi: 10.2337/cd21-0044. Clin Diabetes. 2022. PMID: 35983415 Free PMC article. No abstract available. - Binding Domain Characterization of Growth Hormone Secretagogue Receptor.
Sun Y, Ye X, Kennedy H, Smith AGA, Smith RG. Sun Y, et al. J Transl Int Med. 2022 Jul 2;10(2):146-155. doi: 10.2478/jtim-2022-0033. eCollection 2022 Jun. J Transl Int Med. 2022. PMID: 35959447 Free PMC article. - Effects of Short-term Fasting on Ghrelin/GH/IGF-1 Axis in Healthy Humans: The Role of Ghrelin in the Thrifty Phenotype.
Hollstein T, Basolo A, Unlu Y, Ando T, Walter M, Krakoff J, Piaggi P. Hollstein T, et al. J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3769-e3780. doi: 10.1210/clinem/dgac353. J Clin Endocrinol Metab. 2022. PMID: 35678263 Free PMC article. - Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.
Yau M, Rapaport R. Yau M, et al. J Endocr Soc. 2021 May 22;5(7):bvab096. doi: 10.1210/jendso/bvab096. eCollection 2021 Jul 1. J Endocr Soc. 2021. PMID: 34141995 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous